Vor Biopharma (VOR)Ra Capital Management, L.P. opened a new position $96.6M

1.98M

Shares reported

1.2%

Disclosed portfolio weight

$96.6M

Reported value

Holdings as of

Sep 30, 2025

Filed

Nov 14, 2025

The story around this disclosure

Every dated public record OQRO holds about the company from 60 days before to 120 days after, oldest first. It shows what was going on; none of it is a stated reason for the trade.

1. Sep 11, 2025Insider10% owner sold ~$521K of VOR shares in the open market
2. Sep 12, 2025Insider10% owner sold ~$526K of VOR shares in the open market
3. Sep 15, 2025Insider10% owner sold ~$656K of VOR shares in the open market
4. Sep 16, 2025Insider10% owner sold ~$689K of VOR shares in the open market
5. Sep 17, 2025Company filing · Form 8-K · Shareholder rights, Other newsChanged the rights of its shareholders, and reported other company news
6. Nov 2, 2025Company filing · Form 8-K · Executive change, Reg FDChanged a top executive or board member, and shared information with investors“On November 2, 2025 (the “Effective Date”), Vor Biopharma Inc. (the “Company”) and Dr. Qing Zuraw, the Company’s Chief Development Officer, entered into an amendment (the “Employment Agreement Amendment”) to Dr. Zuraw’s employment agreement with the Company dated July 17, 2025 (the “Employment Agreement”).”

What came next

1. Dec 5, 2025Company filing · Form 8-K · Executive changeChanged a top executive or board member“On December 5, 2025 (the “ Effective Date ”), the board of directors (the “ Board ”) of Vor Biopharma Inc. (the “ Company ”) approved a stock option repricing whereby the exercise price of certain outstanding options to purchase shares of the Company’s common stock (the “ Common Stock ”) under the Company’s Amended and Restated 2021 Equity Incentive Plan (“ 2021 Plan ”) and the Company’s 2023 Inducement Plan (the “…”
2. Dec 15, 2025Company filing · Form 8-K · Material agreement, Unregistered sharesChanged a top executive or board member, and signed an important agreement (and 2 more items)“On December 17, 2025, Sarah Reed, a member of the Company’s Board of Directors (the “Board”), delivered her notice of resignation to the Board, effective immediately.”
3. Dec 31, 2025Company filing · Form 8-K · Executive changeChanged a top executive or board member“On December 31, 2025, Vor Biopharma Inc. (the “Company”) entered into a separation agreement (the “Separation Agreement”) with Dr. Qing Zuraw, the Company’s Chief Development Officer, as a result of Dr. Zuraw’s decision to pursue other opportunities.”
4. Jan 12, 2026Company filing · Form 8-K · Results, Reg FDReported its results, and shared information with investors

How to read SEC Form 13F-HR

Form 13F is the quarterly report in which investment managers that oversee $100 million or more list the US-listed stocks and some other securities they held on the last day of the quarter.

Full guide: What is an SEC Form 13F?

What else is on file for Vor Biopharma

For Vor Biopharma, OQRO holds 1 fund holdings report (13F) dated in the last 90 days.

These are records OQRO holds, counted by their date, not a measure of how much trading took place. Routine paperwork such as option exercises and tax withholding is left out. Everything for the company is on its VOR page.

How this filing works

• SEC Form 13F

Other disclosures at Vor Biopharma

• SEC Form 13F-HRAug 14, 2026
• SEC Form 13F-HRFeb 17, 2026
• SEC Form 13F-HRFeb 17, 2026
• SEC Form 13F-HRFeb 13, 2026
• SEC Form 4Sep 19, 2025
• SEC Form 4Sep 15, 2025

Everything OQRO holds on this company is on its VOR page.